This analysis groups all samples that contain a mutation of either SRSF2|U2AF1|SF3B1|ZRSR2|ASXL1|EZH2|BCOR|STAG2 as secondary AML. Variant Summary column in BEATAML2 clinical data was used to perform this work.

Samples that contain a mutation for NPM1, TP53, core-binding fusion in RUNX1/RUNX1T1 or CBFB/MYH11, or 11q23 were marked as negative mutations, aka de novo AML. 
